LifeWealth Investments LLC Purchases New Stake in Pfizer Inc. (NYSE:PFE)

LifeWealth Investments LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,001 shares of the biopharmaceutical company's stock, valued at approximately $371,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the 4th quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC acquired a new position in Pfizer during the 4th quarter worth $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 1.2%

Shares of NYSE PFE traded up $0.29 during mid-day trading on Tuesday, hitting $23.61. 36,119,931 shares of the company traded hands, compared to its average volume of 41,080,360. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market capitalization of $134.23 billion, a price-to-earnings ratio of 16.74, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average of $23.33 and a two-hundred day moving average of $25.13.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.82 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.29%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.